Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Back

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Completed

Open to: FEMALE

Age: 18.0 - N/A

Brighton Brighton Brighton Nottingham Nottingham Nottingham Nottingham Truro, Cornwall Truro Truro

Medical Conditions

Breast Neoplasms
Triple Negative Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2013 Mar 2015

Publications

"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26."; "29373071"; "Kumar V, Yu J, Phan V, Tudor IC, Peterson A, Uppal H. Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer. JCO Precis Oncol. 2017 Nov;1:1-19. doi: 10.1200/PO.17.00075."; "35172518"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 160 mg administered as four soft gelatin capsules orally once daily

Intervention Arm Group : Enzalutamide;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Clinical Investigation and Research Unit
    Brighton
    England
    BN2 5BE
  • Pharmacy Department
    Brighton
    England
    BN2 5BE
  • Radiation Safety Service, Medical Physics Department
    Brighton
    England
    BN2 5BE
  • Histopathology Department
    Nottingham
    England
    NG5 1PB
  • Nottingham University Hospital
    Nottingham
    England
    NG5 1PB
  • Pharmacy Department
    Nottingham
    England
    NG5 1PB
  • Radiology Department
    Nottingham
    England
    NG7 2UH
  • Royal Cornwall Hospitals NHS trust
    Truro, Cornwall
    England
    TR1 3LJ
  • Department of Radiology
    Truro
    England
    TR1 3LJ
  • Pharmacy Department
    Truro
    England
    TR1 3LJ


The study is sponsored by Pfizer and is in collaboration with Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc..




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT01889238
Last updated 07 February 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top